<DOC>
	<DOCNO>NCT02683889</DOCNO>
	<brief_summary>This study evaluate use Acthar patient undergo renal transplantation measure rate FSGS recurrence .</brief_summary>
	<brief_title>Use Acthar Patients With FSGS That Will Undergoing Renal Transplantation</brief_title>
	<detailed_description>This prospective study enrol renal transplant recipient primary native kidney disease FSGS . Primary endpoint rate recurrence FSGS see renal transplant biopsy rate proteinuria . Secondary endpoint renal function transplantation The target subject number 20 patient target population primary FSGS patient . By current data , FSGS recur 23 % patient . Therefore , would expect least 4 patient develop recurrent FSGS renal transplantation . Screening perform Principal Investigator kidney transplant evaluation clinic wait list kidney transplant evaluation clinic . All patient FSGS maintenance immunosuppression belatacept ( EBV positive ) , prograf , cellcept prednisone . If one year patient stable rejection , stop prograf continue solely belatacept , cellcept prednisone . Dosage Administration Acthar The dose acthar give every enrolled patient 80 unit twice week 6 month .</detailed_description>
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>FSGS To receive either live donor decease donor kidney transplant Not FSGS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>